Biotech Values

[DewDiligence]

I don’t know what the Judge’s legal obligation to the parties vis-à-vis scheduling might be; however, Rick Shea (MNTA’s CFO) stated plainly that the Judge presiding over the Lovenox patent case set the trial schedule after ascertaining that Teva was not close to FDA approval.

In contrast to the kind of murky remark Shea made about the rationale for MNTA’s Dec 2010 financing, Shea’s statement on the Lovenox trial schedule could readily be refuted if it were false or misleading.